Introduction {#sec1-2055207618789322}
============

Solid organ transplantation is the treatment of choice for patients with end-stage organ failure. Patients eligible for an organ transplant represent a complex population, which require pre-transplant evaluation and preparation followed by post-transplant lifelong monitoring and interactions with a multidisciplinary medical team. Telemedicine allows health care professionals to interact with patients remotely using digital healthcare technology.^[@bibr1-2055207618789322][@bibr2-2055207618789322]--[@bibr3-2055207618789322]^ This technology provides patients opportunities for enhanced access to their healthcare team from the comfort of their own home, and has potential to promote active engagement in health, which may translate to improved patient satisfaction and outcomes.^[@bibr4-2055207618789322][@bibr5-2055207618789322]--[@bibr6-2055207618789322]^ Implementation of telemedicine in high-risk patient populations, such as transplant patients, provides opportunities for continuous interactions with patients, as Schmid et al. demonstrated a positive impact in practice.^[@bibr7-2055207618789322]^ In addition, this practice enables healthcare systems to overcome the physical barriers of space constraints in outpatient areas.^[@bibr8-2055207618789322],[@bibr9-2055207618789322]^ The adoption of telemedicine in clinical practice has increased as the access to digital technology becomes more abundant.^[@bibr8-2055207618789322]^ Studies in transplantation have described use of telemedicine as part of waitlist management to improve quality of life and increase patient knowledge,^[@bibr10-2055207618789322][@bibr11-2055207618789322]--[@bibr12-2055207618789322]^ living donor care to increase patient access and reduce travel costs during donor organ procurement to assess donor organs.^[@bibr11-2055207618789322],[@bibr13-2055207618789322][@bibr14-2055207618789322]--[@bibr15-2055207618789322]^ In the post-transplant phase, telemedicine has been used for patient education to increase patients knowledge about skin cancer risk,^[@bibr16-2055207618789322],[@bibr17-2055207618789322]^ and adherence with laboratory and medication regimens.^[@bibr18-2055207618789322][@bibr19-2055207618789322]--[@bibr20-2055207618789322]^ Studies describing implementation and use of telemedicine for pharmacy services are limited.

The United Network for Organ Sharing (UNOS) and Centers for Medicare and Medicaid Services (CMS) specifically mention the clinical transplant pharmacist as a mandatory component of the multidisciplinary care team.^[@bibr21-2055207618789322]^ A telemedicine clinic can enhance the pharmacist's ability to provide patients with medication education, monitor pharmacotherapy, and enhance medication adherence in a comfortable setting for the patient. Pharmacists can expand their outreach to patients, which ultimately improve quality, outcomes, and efficiency. Telemedicine can strengthen operational workflow for pharmacists, enabling them to have personalized face-to-face interactions with patients. Furthermore, it can enhance communication regarding pharmacotherapy and medication profiles with the multidisciplinary medical team to ensure adherence to program protocols and provision of up-to-date information.^[@bibr22-2055207618789322]^ As transplant pharmacists in a large academic medical center, we established and grew the use of telemedicine to reach our patients. Telemedicine was implemented in an effort to provide better access for patients to pharmacy services in their continuum of care. The purpose of this article is to outline the trials and tribulations we experienced in establishing our pharmacy telemedicine clinic in a kidney and pancreas transplant practice, which represents a high-risk patient population.

Methods {#sec2-2055207618789322}
=======

This single-center, retrospective study summarizes a multi-pronged approach that was instituted to implement a pharmacy telemedicine practice at our institution. This study was approved by the Institutional Review Board. During the initial development stages, a population assessment was performed to examine our patient's access and perceptions with using technology. An internally developed questionnaire was used to ascertain availability of electronic resources (e.g., smart phones, computer, tablet, etc.) and perceived benefits of technology in healthcare. This questionnaire was distributed by our clinical team to transplant patients admitted to the hospital or coming to clinic for post-transplant follow up visits. Secondly, a team of clinical pharmacists developed a standard operating procedure that represents important intervention areas for our transplant patients and donors was created: medication reconciliation, vaccination history, medication teaching, pharmacotherapy and protocol review, medication adherence, and answering medication-related questions. Each element is described in detail below: Medication reconciliation: Maintenance of an accurate medication list in the medical record and for the patient is critical to ensure patient safety and optimal outcomes. Transplant patients are at an increased risk of medication errors due to the frequent transitions of care in the pre- and post-transplant environment, the number of medications required (typical regimens contain up to 12 medications), and the frequent changes needed in their medication regimens following transplantation.Vaccination history: Transplant candidates and recipients are at increased risk of infectious complications. The response to vaccines is diminished in organ failure; hence, it is important for transplant candidates to be immunized early in the course of their disease. Maintaining current vaccination histories can potentially decrease unnecessary healthcare costs for both the patient and our institution.Medication teaching: Pre-transplant: Educating transplant candidates and their families about the safe use of transplant medications is an important proactive step to ensure an understanding of the complex nature of transplant pharmacotherapy and share expectations with the patient before they embark on the transplant journey. Post-transplant: Kidney transplant recipients have a short hospital stay with a limited amount of time to learn and retain information about their discharge regimen. Patients with lower levels of health literacy are particularly vulnerable to adverse drug events. Close follow-up after discharge presents an opportunity to optimize patient understanding about their medications.Pharmacotherapy review and transplant program protocol compliance: Most transplant patients will receive therapy based on the hospital medication management protocol, which coincides with the treatments recommended by respective guidelines and clinical practices. In order to ensure compliance to protocol, patient's course of therapy must be monitored from the start of admission and followed in the outpatient setting to ensure medication use safety.Medication adherence: Adherence to immunosuppressive medications after transplantation is vital in maximizing positive clinical outcomes, yet nonadherence occurs in 30% of transplant recipients.^[@bibr23-2055207618789322]^ Telemedicine visits enable pharmacists to promote adherence and monitor patient progress.Triage to other providers: Interactions that pharmacists have during telemedicine visits may identify opportunities for referral to other disciplines to provide comprehensive services.

Finally, in partnership with the Information Technology Department's Innovation Team, the transplant team created a patient-centered telemedicine workflow while taking into consideration the pharmacist's daily routine ([Figure 1](#fig1-2055207618789322){ref-type="fig"}). Patients were identified for a virtual visit during their index hospitalization for transplant or living donation. During standard medication teaching sessions, required as part of practice, the pharmacy team assessed which patients had access to technology with webcam capabilities (smartphone, laptop, or tablet) and registered patients for a post-transplant virtual pharmacy visit with the outpatient transplant pharmacist after hospital discharge. A member of our pharmacy team created an account and downloaded the in-house developed app to the patient's device. The app utilizes American Well's software development kit, which allows video visits to occur through the American Well platform. The app provides the interface for the video visit, which is encrypted and Health Insurance Portability and Accountability Act (HIPPA) compliant. During this process the pharmacy team member explained the visit structure and expectations to the patient and asked if a test visit was desired. Members of the IT Innovation Team conducted test visits with the patient 24 h prior to the scheduled virtual visit to troubleshoot any potential issues beforehand, saving the pharmacist time during the virtual visit. Figure 1.Transplant pharmacy virtual visit follow-up workflow.

Results {#sec3-2055207618789322}
=======

[Table 1](#table1-2055207618789322){ref-type="table"} summarizes metrics from an overall population assessment of 47 patients. From the individuals surveyed, 37 patients (79%) had a smartphone with 54% (*n* = 20) of these individuals having healthcare-related applications (e.g., any free app that the patient may use for healthy lifestyle---diet and exercise, medical or pharmacy information, insurance, or hospital portals). More than half (*n* = 27, 57%) of patients had access to internet services at home and the majority (*n* = 37, 79%) reported being "comfortable" or "very comfortable and tech savvy" with using technology in daily activities; 91% of individuals indicated that they thought technology can help them manage their healthcare needs better and had already been engaging with their providers through text messaging (*n* = 17, 36%), e-mail (*n* = 12, 26%), and hospital portals (*n* = 13, 28%). Furthermore, 66% (*n* = 31) of respondents were interested in having virtual visits with their healthcare providers. Table 1.Technology assessment survey.(*n* = 47)Age in years, mean (SD)45 (17)Access to technology Smartphone37 (79) Tablet22 (47) Desktop computer20 (43) Laptop computer25 (53) Smartwatch6 (13) None4 (9)Wi-Fi services available at home27 (57)How do you communicate with your healthcare provider In person34 (72) Telephone37 (79) Text message17 (36) E-mail12 (26) Hospital patient portal13 (28) Telemedicine / virtual visit2 (4)

From January through June 2017, 55 transplant patients were eligible and approached to participate in the telemedicine initiative. Almost all, 46/55 patients, were registered for a visit (transplant recipients *n* = 32 and living donors *n* = 14). Of patients not registered, six (66%) patients lacked appropriate technology to conduct the visit at home, and three (33%) had a language barrier. Demographic characteristics are summarized in [Table 2](#table2-2055207618789322){ref-type="table"}. The majority of patients were males (63%), the mean population age was 47 ± 13 years, and patients lived a median of 27 miles away from the transplant center. Over half (52%) of the patients who registered successfully completed a virtual visit. Approximately three-fourths of the patients who completed a visit connected using a mobile device and the remainder using a computer. An interim analysis after the first 18 patients were registered indicated that 55% were "no shows" for their scheduled visit. No-show data is tracked automatically and is determined by the system if a scheduled patient never signs in to the app for their scheduled virtual appointment. In response to this rate, enhancements to the telemedicine platform and workflow were implemented so that the team could send calendar invitations with a 1-h pre-visit reminder. In addition, we implemented test visits with the IT Innovation Team the day before the clinician visit. These changes resulted in a reduction in "no shows" by 7%. Time from hospital discharge from the index transplant hospitalization to the telemedicine visit for the overall cohort was 5.4 days. While not significantly different, the time to a scheduled visit for patients with a successful visit versus those who were no shows was 4.5 versus 6.4 days, respectively (*p* = 0.28). The average visit duration was 11.6 ± 8 min. Medication reconciliation was performed for 24 patients, of which 6 (13%) required adjustment to their medication list. An average of 1.2 ± 0.4 medication changes were updated in the medical record. All patients were educated about the importance of vaccines and about their discharge medication regimens. The team identified an area of protocol adherence deviation in the case of a patient who ran out of pain medication and was able to triage this issue to the prescribers on the multi-disciplinary care team to provide a prescription for the patient; of note, this happened during a visit that occurred during off hours (7 pm) from a typical workday. During the visits, patients were asked three questions to assess adherence to their regimen: (1) *Have you experienced side effects and decided to stop taking your medication?*; (2) *Do you think it is safe to stop taking your transplant medicine because you feel healthy?*; (3) *Is it difficult for you to follow your transplant medication treatment regimen?* To date, all patients have responded favorably (100% of patients answered no to each question), indicating that they were following instructions provided by the healthcare team. The majority of patients asked questions about pain management and were counseled to schedule pain medications, rather than waiting until they experienced discomfort. Table 2.Baseline demographic characteristics.(*n* = 46)Age in years, mean (SD)47 (13)Male, *n* (%)29 (63)Race White29 (63) Black11 (24) Asian3 (6.5) Hispanic3 (6.5)Distance from transplant center to patients home in miles, median (IQR)27 (17--44)Patient type, *n* (%)Transplant recipients32 (70) Living donor transplant type13 (41)Living donor patients14 (30)Number of active medications, median (IQR) Transplant recipients11 (9--14) Living donor patients1 (0--2)

Discussion {#sec4-2055207618789322}
==========

Integrating a novel approach to healthcare delivery in a high-risk patient population of transplant recipients has revolutionized our practice model. Our study contributes to the existing literature by describing a telemedicine implementation for transplant pharmacy services, which are currently limited. Prior to implementing telemedicine, transplant pharmacists at our center were limited to practice as inpatient clinicians. This technology and practice model enhancement has enabled us to provide pharmacy services in the continuum of care as patient's transition from the hospital and clinic to home setting. This practice has been important to ensure the safe and effective use of medications for our patients; for example, we have had an opportunity to identify and quickly resolve a patient care issues related to pain management, which may have gone unnoticed or led to an emergency department visit had we not seen the patient. The described pharmacy telemedicine practice model can be generalized to other institutions and patient populations with complex medication regimens and multiple comorbidities who may benefit from a pharmacy consultation. The essential key to success is involving key stakeholders early in the development process to ensure adequate support and collaboration. Our telemedicine practice has continued and expanded in scope to the pre-transplant phase of care with an emphasis on medication reconciliation and education. All patients are offered a 1-month follow up check-in after the initial visit, which has allowed the pharmacy team to establish a relationship with patient in advance of their transplant surgery.

This is a newly developed practice model and long-term follow up is not yet available. Currently, the patients in this cohort have only had one post-transplant telemedicine visit and adherence assessments were only conducted at a single time point (early post-transplant) at the first telemedicine encounter. As our population grows and follow-up time progresses, we will have opportunities to further engage with patients through additional telemedicine visits to reassess our six key elements approach. Strategies to minimize no-show rate continue to be explored; in addition to the standard app, email and calendar reminders, patients are encouraged to set an alarm that will remind them about the upcoming appointment. Patients who are not seen by a pharmacist because they did not show to a visit are contacted by telephone on three occasions to reschedule their appointment. Transplant centers care for unique high-risk patients that must be seen and cared for locally in a routine, life-long fashion. Telemedicine allows expansion of services without requiring physical real estate. In addition, telemedicine visits increase access to the transplant pharmacist and allow patients to benefit from clinical services and learn in a non-overwhelming, comfortable, and familiar setting.
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